Demand for the immunology drug Dupixent was the main driver behind the financial performance of Sanofi SA in the first quarter, which otherwise experienced sales declines for legacy medicines and drugs for neurological diseases. Group sales were €8.59 billion for the quarter, representing a decline of 4.3% from a year earlier. However, on a constant exchange rate basis, sales rose by 2.4%.
